n
 
About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Friday, September 1st, 2017

The QualityStocks
Daily Stock List

graphic
graphic

Guided Therapeutics, Inc. (GTHP)

OTCStars, BestDamnPennyStocks, DSR News, PHUB News, TheNextBigTrade, TopPennyStockMovers, SmallCapVoice, PennyTrader Publisher, Pennystocktweeters, NYC Marketing Inc., Stock Beast, PennyStocks24, PennyStockLocks, ResearchOTC, Stock Commander, StockRockandRoll, AllPennyStocks, and Momentum Trades reported on Guided Therapeutics, Inc. (GTHP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Guided Therapeutics, Inc. is the creator of a quick and painless testing platform. This platform is for the early detection of disease founded on the Company's patented biophotonic technology, which utilizes light to detect disease at the cellular level. Listed on the OTC Bulletin Board, Guided Therapeutics is headquartered in Norcross, Georgia.

The Company’s initial product is the LuViva® Advanced Cervical Scan. This is a non-invasive device used to detect cervical disease promptly and at the point of care. The LuViva® Advanced Cervical Scan is an investigational device. It is limited by federal law to investigational use in the United States. The design of LuViva® is as a quick, painless test that, unlike Pap smears and HPV testing, does not require a tissue sample or the delay of laboratory analysis.

LuViva® scans the cervix with light and uses spectroscopy to measure how light interacts with the cervical tissue. Spectroscopy identifies chemical and structural indicators of pre-cancer that may be below the surface of the cervix or misdiagnosed as benign. The technique is named biophotonics. Biophotonics is the science of generating and harnessing light to image, detect, and also manipulate biological materials.

The LuViva® Advanced Cervical Scan technology (in a multi-center clinical trial, with women at risk for cervical disease) was able to detect cervical cancer up to two years earlier than conventional modalities, according to published reports. The device is utilized in combination with the LuViva® Cervical Guide single-use patient interface and calibration disposable.

The LuViva® Advanced Cervical Scan is under U.S. Food and Drug Administration (FDA) Premarket review. Furthermore, Guided Therapeutics is developing a non-invasive test for the early detection of esophageal cancer using this technology platform.

In late May of this year, Guided Therapeutics announced that it received an order for 10 additional LuViva® Advanced Cervical Scans for Indonesia. This order brought to 24 the number of LuVivas and over 7,000 the number of single use Cervical Guides sold to Indonesia. Additional orders of Cervical Guides are expected later in 2017.

Recently, Guided Therapeutics announced that it re-opened discussions with the FDA concerning U.S. premarket approval of the Company’s LuViva® Advanced Cervical Scan. Its decision was encouraged by a constructive outcome from its earlier face-to-face meeting with the FDA and a perceived more favorable environment for device approvals under the new Presidential administration, along with a recent rise in device approvals at the FDA.

Guided Therapeutics’ plan is to re-file for approval of its LuViva® Advanced Cervical Scan. The Company plans on conducting a new clinical study to confirm earlier results already submitted to the FDA.

Guided Therapeutics, Inc. (GTHP), closed Friday's trading session at $0.04, up 33.33%, on 283,087 volume with 46 trades. The average volume for the last 60 days is 161,648 and the stock's 52-week low/high is $0.02/$4.00.

RedHawk Holdings Corp. (IDNG)

TopPennyStockMovers, Real Pennies, Greenbackers, Fast Money Alerts, Mad Money Picks, The Observer, Innovative Marketing, Penny Stock General, Stock Shock and Awe, PennyStocks24, and Hot Stock Profits reported earlier on RedHawk Holdings Corp. (IDNG), and we also report on the Company, here at the QualityStocks Daily Newsletter.

RedHawk Holdings Corp. is a diversified holding company listed on the OTC Markets. The Company, via its subsidiaries, engages in the sales and distribution of medical devices, sales of branded generic pharmaceutical drugs, commercial real estate investment and leasing, sales of point of entry full-body security systems, and specialized financial services. RedHawk Holdings was formerly Independence Energy Corp. RedHawk’s subsidiaries are RedHawk Medical, EcoGen Europe, RedHawk Energy Corp., and RedHawk Land & Hospitality. RedHawk Holdings is based in Louisiana.

RedHawk Energy holds the exclusive U.S. manufacturing and distribution rights for the Centri Controlled Entry System. This System is a unique, closed cabinet, nominal dose transmission full body x-ray scanner.

Through its RedHawk Medical Products business unit, RedHawk Holdings sells WoundClot Surgical - Advanced Bleeding Control; the Sharps and Needle Destruction Device (SANDD™); the Carotid Artery Digital Non-Contact Thermometer, and Zonis®.  

RedHawk Medical Products UK Limited is a specialist medical device company. It delivers innovative product solutions to healthcare markets in the United Kingdom (UK), Europe and the Middle East.

EcoGen Europe’s dedication is to healthcare and the NHS. Its commitment is to securing savings across the drug budget in primary care. This is while providing innovation to drive patient care in the acute setting. Last month, RedHawk Holdings announced that it recently completed its financial and legal due diligence and upon execution of final agreements, it will increase its ownership interest in EcoGen Europe to 75 percent.

RedHawk’s financial services revenue is from brokerage services earned in association with debt placement services and investments in oil and gas exploration and production. The Company’s real estate leasing revenues come from varied commercial properties under long-term lease. Moreover, its real estate investment unit holds limited liability company interest in different commercial restoration projects in Hawaii.

EcoGen Europe has signed an exclusive agreement to license and supply a new non-patent infringing generic spray formulation of Sildenafil Citrate in the UK. EcoGen will market the new spray under the brand name Azulvig. EcoGen expects to start marketing Azulvig after receipt of final UK regulatory approval.

RedHawk Holdings has acquired a stake in Tigress Energy Partners. RedHawk agreed to acquire up to a 25 percent interest in Marlin USA Energy Partners, LLC, the minority owner of Tigress Energy Partners, LLC (TEP). The majority ownership of TEP is held by Tigress Holdings, LLC, a limited liability company majority-owned by Cynthia DiBartolo, Chief Executive Officer of Tigress Financial Partners LLC (TFP).

RedHawk Holdings has also completed the re-engineering of its Sharps and Needle Destruction Device (SANDD). It received pre-market clearance from the U.S. Food and Drug Administration (FDA) for the sale of SANDD in the U.S.  RedHawk Medical Products acquired the tangible and intangible property rights to SANDD (formerly known as the Disintegrator™ Insulin Needle Destruction Unit) in December 2015.

In early August, RedHawk Holdings announced that its wholly-owned real estate subsidiary, RedHawk Land & Hospitality LLC, entered into new agreements for the lease of its two commercial properties in Lafayette, Louisiana. The Company said it entered into a new triple-net lease agreement with the Louisiana 3rd Circuit Court of Appeal to renew and extend the present lease term to December 31, 2022. The new lease agreement was effective August 1, 2017 and included certain rate increases.

RedHawk Holdings Corp. (IDNG), closed Friday's trading session at $0.0079, even for the day, on 61,747 volume with 7 trades. The average volume for the last 60 days is 107,820 and the stock's 52-week low/high is $0.0032/$0.0398.

All for One Media Corp. (AFOM)

OTC Markets, Street Register, MarketWatch, InvestorsHub, and Barchart reported on All for One Media Corp. (AFOM), and today we report on the Company, here at the QualityStocks Daily Newsletter.

All for One Media Corp. is a tween marketing company listed on the OTCQB. The estimation is that the tween demographic is responsible for no less than $260 billion yearly in direct sales in the U.S. alone. Called “Generation I” for "Internet," this generation's tweens represent the first demographic to have had only known life with the Internet and social media. Essentially, All for One Media is a marketing brand changing the mindset of tweens that bullying is unacceptable.  All for One Media has its corporate office in Mount Kisco, New York.

At present, the Company is producing "Crazy For the Boys." All for One Media, through entertainment, is working to deliver a message, which will resonate with kids to impact the epidemic of bullying and cyber-bullying. Also, the Company is working to help individuals who have been affected by bullying to deal with it in a positive and constructive way.

“Crazy For The Boys” is a full length coming of age musical dramedy. It features Groovy Tuesday music and choreography. The film tells the story of five high school girls from five very different cliques who must work together to run their school’s anti-bullying organization. The film features original pop songs concerning peer pressure, unrequited love, and teen angst.

The expectation is that “Crazy For The Boys” will generate revenues from a number of sources. These include domestic and global distribution, video on demand (VOD), merchandising, soundtrack, live performances, and other ancillary sources.

All for One Media has initiated the recording of the sixteen songs that will be included in "Crazy for the Boys", as well as included on the Soundtrack for the movie. Several songs will be produced by multi-platinum Producer Jeff Coplan. Recording began on May 2, 2017 at legendary studio "The Jungle Room" in Glendale, California.

In May of this year, All for One Media announced that it received a commitment letter from its production partner Sunset Pictures. This is for domestic distribution for the motion picture Crazy for the Boys through its output deal with 20th Century Fox, inclusive of theatrical release via Atlas Distribution, and all ancillary rights including Netflix, Cable, and Network TV, and DVD, Blue ray, VOD, Digital, and more. Sunset Pictures will facilitate Print and Ad Funds to boost the marketing of the theatrical release and the marketing of the film.

Recently, All for One Media, by way of its wholly-owned subsidiary, Crazy for the Boys movie, LLC, announced the casting of former "Saturday Night Live" star, Cheri Oteri in its upcoming feature film as the Principal of JFK High School. The upcoming musical dramedy began shooting on July 5, 2017 in Savannah, Georgia. Cheri Oteri is famous for being one of the cast members on Saturday Night Live from 1995 to 2000. Crazy for the Boys is being marketed as a modern day "Grease." Crazy for the Boys is targeting a Spring Break 2018 theatrical release. 

All for One Media Corp. (AFOM), closed Friday's trading session at $0.0183, down 20.09%, on 35,878 volume with 6 trades. The average volume for the last 60 days is 104,809 and the stock's 52-week low/high is $0.0175/$0.55.

Blake Insomnia Therapeutics, Inc. (BKIT)

Daily Stock Picks and MarketWatch reported on Blake Insomnia Therapeutics, Inc. (BKIT), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Blake Insomnia Therapeutics, Inc. is a pharmaceutical company headquartered in New York, New York. Blake centers on the provision of insomnia remedies in the U.S. The Company beforehand went by the name Book It Local, Inc. It changed its corporate name to Blake Insomnia Therapeutics, Inc. in September of 2015. Formed in 2012, Blake Insomnia Therapeutics lists on the OTC Markets.

The Company’s Zleepax™ (ZLX-1) is the first sleep aid with beta blockers as the major active agent. This compound has demonstrated efficacy without producing side effects - identified as the #1 problem with contemporary sleep medication. The basis of ZLX-I is on advanced new beta blockers, for example Nebivolol.

Zleepax™ (ZLX-1) acts by lessening the physical symptoms of stress that keep people awake at night. Blake Insomnia Therapeutics states that according to patients, the #1 problem with traditional sleeping pills is residual daytime sedation. Additionally, the Company states that the potential for tolerance build-up and addiction are also major perceived disadvantages. Based on beta blockers, Zleepax™ lessens these and many other unwanted side effects.

ZLX-1’s United States Patent and Trademark Office (USPTO) Patent Application is (EP20080758258). In 2007, Blake Insomnia Therapeutics filed patent application EP20080758258, covering the use of specific beta blockers, alone or in combination with other anti-insomnia drugs, for the treatment of stress-related insomnia. Phase II is scheduled for this year; Phase III is scheduled for 2019; and the projected launch date is 2022.

Blake Insomnia Therapeutics and Sajo Consulting LLC previously announced the completion of a Joint Venture (JV) agreement for the development and commercialization of a series of oral drug products to assist in the treatment of insomnia. The JV’s intention is to develop products to treat transient insomnia using Blake Insomnia Therapeutics’ proprietary Zleepax™ formula.

Last week, Blake Insomnia Therapeutics announced that it submitted its clinical trial application (CTA) for Phase II clinical testing to Health Canada. The Phase II clinical trial will investigate the effect of ZLX-1 on insomnia. It is a vital milestone for this novel insomnia treatment on the path to final approval. The trial results are essential for validating the ZLX-1 concept and for designing the Phase IIb trial to follow.

Blake Insomnia Therapeutics, Inc. (BKIT), closed Friday's trading session at $0.068, up 36.00%, on 77,328 volume with 18 trades. The average volume for the last 60 days is 102,964 and the stock's 52-week low/high is $0.041/$1.60.

Versus Systems, Inc. (VRSSF)

TradingView, Barchart, and InvestorsHub reported on Versus Systems, Inc. (VRSSF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Versus Systems, Inc. has developed a proprietary in-game conditional prizing and promotions engine. It enables players to compete for and win real prizes from brands that they care about while playing their favorite games. Fundamentally, the Company’s white-label platform gives players the opportunity to play for the things they love, inside of the games they love.

Versus Systems lists on the OTC Markets Group’s OTCQB. The Company is based in Vancouver, British Columbia.

Versus Systems permits game developers and publishers to provide players with prizes, which players can win inside their favorite games. This adds engagement as well as a new dimension to gameplay. Versus prizing includes gear, apparel, tickets, energy drinks, and downloadable content from brands such as Tier 1, Han Cholo, Rockstar Energy Drink, and others.

Recently, Versus Systems was named #13 on the 100 Top Companies for Millennial Women by foremost women’s platform Mogul. The Company received recognition alongside Nike, Pinterest, and Deloitte for their efforts to attract, promote, as well as empower women in the workplace.

Last month, Versus Systems announced that it has partnered with 704Games to provide in-game prizing in their upcoming titles.  704Games is working with the Company’s prizing and promotions platform to provide players with opportunities for in-game prizing and real-world rewards in their upcoming titles on mobile and console.

704Games released NASCAR Heat Mobile this past spring. This is the first authentic NASCAR racing game on mobile to feature 40 stock cars racing at the same time. In addition, 704Games recently announced the upcoming release of NASCAR Heat 2. It will be available on Xbox One, Playstation 4, and PC.

Mr. Matthew Pierce, Chief Executive Officer of Versus Systems, said: “We are thrilled to be working with 704Games to give gamers the opportunity to win real prizes from their favorite brands inside their favorite racing games. This is a fantastic partnership for us and we look forward to building Versus prizing into all of 704Games upcoming titles.”

Versus Systems, Inc. (VRSSF), closed Friday's trading session at $0.3007, up 6.33%, on 10,830 volume with 5 trades. The average volume for the last 60 days is 14,129 and the stock's 52-week low/high is $0.1045/$0.4582.

graphic

The QualityStocks
Company Corner

graphic
graphic

Lexaria Bioscience Corp. (CSE:LXX) (OTCQB:LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP). Today, Lexaria Bioscience Corp. closed trading at $0.3762, up 7.58%, on 87,573 volume with 54 trades. The stock’s average daily volume over the past 60 days is 82,185 and its 52-week low/high is $0.11/$0.699.

Lexaria Bioscience Corp. (LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. Though boasting a wide range of health benefits, cannabinoids are traditionally poorly absorbed by the body's gastrointestinal tract. To achieve higher effectiveness, consumers usually default to smoking. Lexaria provides a superior administration method by delivering hemp oil ingredients – or through locally licensed partners, cannabis oil ingredients – through a patented process within food products.

The key differentiator between Lexaria's products and others on the market is the company's disruptive technology proven to enhance the absorption of orally ingested cannabinoids while improving the "unusual" taste of cannabinoids and allowing for lower overall dosing with higher efficacy. Lexaria is primarily a B2B enterprise, and is in licensing discussions or has existing agreements with companies in Canada, the largest-market states in the USA, and internationally. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within lipids in popular foods. These brands include ViPova™, Lexaria Energy Foods, and TurboCBD™.

In 2015, Lexaria commissioned an independent, third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company's technological process and lipid formulation both improve intestinal absorption as much as 500%. Additional follow-up studies in human volunteers suggested that Lexaria's processed, lipid-infused tea may be more effective in an actual gastrointestinal system than in an in vitro simulation with results indicating as much as a 1,000% increase in overall absorption.

Lexaria also has an R&D partnership with the Canadian government's National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria's unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D are expected to support accelerating B2B relationships – not just in the cannabis industry, but also to support new B2B business relationships in the fields of vitamins, NSAIDs, and nicotine delivery. All of these sectors expected to offer additional future growth potential.

Aside from testing, a critical component of Lexaria Bioscience's business model is a strong intellectual property portfolio that utilizes the most commonly used food processing techniques. As of 2017, the company's patent portfolio includes 19 patent applications filed and pending in more than 40 countries around the world. The most recent patent applications expand Lexaria's lipophilic food and beverage composition claims to include the processing of cannabinoids, vitamins, NSAIDs and nicotine in many of the world's most commonly used food processing ingredients. Lexaria is expecting additional new patent awards both in the USA and internationally in 2017 and 2018.

Royalties play a vital role in Lexaria's revenue-generating business model. The company out-licenses its technology (royalty) to third party partners, and has several deals signed and/or pending. The company's growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has raised more than $50 million in working capital for the companies he has led over the course of his career. He is supported by a team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets. Disclaimer

Lexaria Bioscience Corp. Blog

Lexaria Bioscience Corp. News:

University of British Columbia to Perform Clinical Study on the Cardiovascular and Cognitive Health Effects of Lexaria's TurboCBD

NetworkNewsWire Announces Publication Highlighting Companies Taking Innovative Strides in the Tobacco Industry

Lexaria Announces Exercised Warrants and Options

ORHub, Inc. (ORHB)

The QualityStocks Daily Newsletter would like to spotlight ORHub, Inc. (ORHB). Today, ORHub, Inc. closed trading at $0.62, up 3.33%, on 33,853 volume with 27 trades. The stock’s average daily volume over the past 60 days is 59,635 and its 52-week low/high is $0.20/$2.09.

ORHub, Inc. (ORHB) is a cloud-based software platform designed to transform the business of surgery into a value-based model. The platform empowers care providers at every stage of the surgical process to collaborate, organize, deliver, measure, and reimburse in one intuitive, easy-to-use program. This significantly decreases cost and improves outcomes by eliminating inefficiencies, duplications of effort, and errors and omissions that result from siloed processes in outdated software and poor handoffs from one part of the care process to another.

The need for ORHub is clear. Health care costs are out of control at more than 17% of US GDP, which equates to over $3 trillion per year. With costs rising every year due to an aging population and increasingly expensive treatments, providers are under severe pressure to become more efficient and reduce costs. This is happening because payors are aggressively reducing reimbursements and finally moving away from fee-for-service and toward a performance-based reimbursement system referred to as value-based health care.

Accurately measuring the cost of treating a condition and relating that cost to the patient's outcome is at the heart of value-based health care. Institutions that have adopted this model have reaped savings of 20-40% on their overall cost of care. Unfortunately, today's siloed IT systems are fundamentally at odds with this process. Legacy health care solutions come from a fee-for-service world and have reinforced the problem and produced a system with erratic quality and unsustainable costs. Most health care applications today are incremental improvements on these existing systems or are simple digital implementations of antiquated pen-and-paper processes.

Providers wanting to practice value-based health care need value-based software. ORHub creates a value-based solution that will revolutionize surgical care delivery by tracking the cost of treating a condition from diagnosis to discharge, and tracking outcomes that resulted from that treatment.

In an industry where major IT rollouts traditionally cost millions of dollars and take an average of eighteen months, pilot installations of ORHub have been completed in less than a month. By avoiding integration with legacy systems completely through a radically comprehensive and collaborative approach, providers see results right away. This approach produces real-time metrics in a uniform manner at any institution, which makes it ideal for large providers looking to make improvements across the board at multiple facilities.

ORHub started as a pilot program developed in cooperation with a major Southern California hospital. It has since expanded operations into a second facility at the number two non-profit hospital system in the US. Three additional pilot programs are scheduled prior to a national launch. The company has raised more than $1.6 million as of January 2017.

The company is also a showcase member of the startup program at Microsoft, which has been a key partner by providing financial assistance, strategy, introductions to influencers and mentors, and access to its sales organization who see ORHub as an exciting partner to expand the utilization of Microsoft Surface devices and Azure Cloud. Microsoft is funding a major case study in partnership with Intel about the impact of ORHub on participating institutions to be concluded sometime in Q2 2017.

ORHub's leadership team is helmed by Colt Melby, who was appointed CEO in 2016 and has been crucial to developing and executing the company's business strategy. Mr. Melby's extensive business experience includes the NASDAQ uplisting of Smith and Wesson (now American Outdoor Brands), CUI Global Inc., and Quest Resource Holdings Corp. His wealth of information and relationships have been vital in helping the company go from concept to production in institutional medicine in less than a year.

Delivering surgical care to a single patient is a complex process that may take half a dozen companies and more than a dozen departments cooperating inside and outside the care facility. ORHub simplifies and streamlines this process by enabling vendors, providers, and surgeons to collaborate on providing care. Disclaimer

ORHub, Inc. Blog

ORHub, Inc. News:

ORHub, Inc. Announces Major Expansion of Operations with Launch and Adoption of Orthopedic Service Lines

ORHub, Inc. Signs National Sales Partner to Launch Transformative Medical Software in Major U.S. Markets

ORHub, Inc. Introduces Fourth Medical Software Service Line, Continuing Rapid Expansion Strategy

Kootenay Zinc Corp. (CSE:ZNK) (OTCQB:KTNNF)

The QualityStocks Daily Newsletter would like to spotlight Kootenay Zinc Corp. (KTNNF). Today, Kootenay Zinc Corp. closed trading at $0.0618, up 2.49%, on 45,800 volume with 9 trades. The stock’s average daily volume over the past 60 days is 26,736, and its 52-week low/high is $0.0308/$0.59.

Kootenay Zinc Corp. (KTNNF) is a mineral exploration and development company focused on discovering large-scale sedimentary-exhalative ("SEDEX") zinc deposits. Based in Vancouver, British Columbia, the company is ideally positioned near its primary target, the Sully Property, located 18 miles east of the world-class Sullivan Mine.

Of the 22 raw materials tracked by the Bloomberg Commodity Index, zinc was the best-performing base metal in 2016. Based on a widening global supply deficit, outlook for the commodity remains strong. As the most closely tied base metal to the Chinese economy, zinc demand and prices are expected to rise well into the year 2020, putting increased pressure on zinc supply.

For 2017, Goldman Sachs has predicted a 360,000 ton shortage of zinc, along with a subsequent rise in zinc prices to $2,500 per metric ton in the first half of the year. Zinc continues to make history in the metals exchange, driving significant interest in the market amid supply constraints in concentrates and refined metal drive prices.

Ready to claim its share of the market, Kootenay Zinc is focused on its Sully Property. It comprises 1,375 hectares and overlies rocks of similar age and origin as those which host the legendary Sullivan deposit. The Sullivan mine was discovered in 1892, and is known to be one of the world's largest SEDEX deposits. Over its 100-year lifetime, Sullivan produced approximately 150 million tonnes of ore, including approximately 300 million ounces of silver, 8 million tonnes of zinc and 8 million tonnes of lead.

Notably, geophysical data suggests that Kootenay Zinc's Sully project and Sullivan share many geological features:

  • Strata at Sully are in the same sedimentary basin as the Sullivan mine
  • The exact stratigraphic time horizon at which Sullivan formed is present at Sully
  • Filtered AeroMag anomalies coincident with Sullivan Time at Sully appear similar to Sullivan
  • Gravity anomaly at Sully indicates excess mass of comparable magnitude to Sullivan
  • Pb-Zn is present as traces in outcrop, drill core and in a soil geochemical anomaly

The squeeze in zinc supplies particularly affects China, which is both the world's largest zinc consumer and its largest producer, with 4.9 million tons of output in 2015. Chinese manufacturers are now being forced to import zinc for use in cars, household appliances, paints, rubber products and smartphones.

Zinc's rally shows no sign of slowing down in the near future, and companies that currently occupy stake in a zinc deposit find themselves in an enviable position over miners rushing to find new reserves. With its Sully Project, Kootenay Zinc could be on track to capture its share of the market, guided by a management team of mining directors and executives that currently lead some of the world's best mining companies and have been involved in world-class discoveries which sold for billions of dollars. The company's technical team includes industry experts that have worked on mega-mining projects, including the Sullivan and Voisey Bay projects. Disclaimer

Kootenay Zinc Corp. Company Blog

Kootenay Zinc Corp. News:

Sully Project - E3 Target Drilling Underway

Kootenay Zinc Corp.: Sully Project Exploration Update

NetworkNewsWire Releases Exclusive Audio Interview with Kootenay Zinc Corp. (KTNNF)

InMed Pharmaceuticals, Inc. (CSE:IN) (OTCQB:IMLFF)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals, Inc. (IMLFF). Today, InMed Pharmaceuticals, Inc. closed trading at $0.219, up 1.86%, on 146,165 volume with 75 trades. The stock’s average daily volume over the past 60 days is 283,424, and its 52-week low/high is $0.061/$0.72.

InMed Pharmaceuticals, Inc. (IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver.

Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis. This extensive collection of data is derived from both public and propriety-based sources. Leveraging this tool, the company aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases. Per InMed’s website, this type of bioinformatics assessment represents “significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease.”

After discovering these promising active cannabinoids, InMed moves to test and confirm their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company’s proprietary biosynthesis process of cannabinoid manufacturing will be most promising. InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.

The company’s pipeline currently includes two drug candidates in preclinical development, including INM-750 for the treatment of epidermolysis bullosa (EB) and INM-085 for the treatment of glaucoma. Referred to by the Dystrophic Epidermolysis Bullosa Research Association of America as “The Worst Disease You’ve Never Heard Of,” EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. The condition currently has no approved treatment or cure. Through the development of INM-750, InMed is attempting to address this significant unmet medical need. The drug candidate replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.

INM-085, InMed’s second development candidate, is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease.

InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents and developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of C$1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.

The company’s management team has well over a century of combined experience in the biopharmaceutical space. Company CEO Eric Adams has more than 25 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During his time as CEO of enGene Inc., he led the gene therapy startup to a position at the head of the industry.

Joining Adams on the InMed management team are Chief Scientific Officer Dr. Sazzan Hossain; Senior Vice President, Clinical and Regulatory Affairs Alexandra D.J. Mancini; SVP, Corporate Strategy & Investor Relations Chris Bogart; and Chief Financial Officer Jeff Charpentier, as well as Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM.

Muhammed, in particular, has an extensive history in the pharmaceutical industry, having previously served as an executive of GW Pharmaceuticals, a global leader in the development of cannabinoid-based medicines. During his time as Associate Medical Director of that company, Muhammed played an instrumental role in the development and FDA approval of one of the first cannabis drugs. This GW Pharmaceuticals development program coincided with a sharp rise in share price from less than $9 in 2013 to more than $129 today, with the company’s current market value totaling more than $2.9 billion. Disclaimer

InMed Pharmaceuticals, Inc. Company Blog

InMed Pharmaceuticals, Inc. News:

InMed Announces Appointment of Creative Capital Media

InMed Announces Publication in European Journal of Pain

InMed Pharma Advances Cannabinoid EB Therapy -- CFN Media

Patriot One Technologies, Inc. (TSX.V:PAT) (OTCQB:PTOTF)

The QualityStocks Daily Newsletter would like to spotlight Patriot One Technologies, Inc. (PTOTF). Today, Patriot One Technologies, Inc. closed trading at $0.53, off by 0.23%, on 32,448 volume with 21 trades. The stock’s average daily volume over the past 60 days is 52,528, and its 52-week low/high is $0.4665/$1.49.

Patriot One Technologies, Inc. (TSX.V: PAT) (OTCQB: PTOTF) is leveraging seven years of development to create powerful technologies that mitigate security risks by detecting concealed weapons via novel radar technology.

Developed through a NATO-funded project at McMaster University, Patriot One's disruptive NForce CMR1000 technology is the first cost-effective solution available for active shooter prevention, the need for which is evidenced by an increasing number of active shooter events in the United States and worldwide.

A recent study that surveyed data going back as far as 1966 demonstrates that there have been significantly more mass shootings in the U.S. than any other country for decades. Statistics for the 46-year period shows that even though America only holds 5% of the world's population, it took count of 31% of all public mass shootings. According to the FBI, there were an astounding 160 incidents from 2000 to 2013 that resulted in 486 people killed and 557 wounded. In years 2014 and 2015, there were nearly six times as many incidents compared to 2000 and 2001. The disturbing trend shows that there will be increasingly more incidents if better preventative measures aren't taken.

Patriot One's patent-pending solution to this alarming progression enables stand-off detection, even on moving targets, with a "cognitive" ability to learn and identify new threats once deployed. The product is not intended to threaten the constitutional rights of legal gun carriers, and it is also void of privacy and health concerns of traditional detection technologies, which require subject compliance, present false positives, and are often slow, inefficient and costly.

In contrast, Patriot One's technology is small in size and can be "covertly" placed in a doorway or hallway to prevent planned attacks in public places like schools, concerts, stadiums, banks, airports, offices, hospitals, shopping centers and other facilities for which there are concerns. With this method of deployment, there is no subject compliance requirement. In addition, because an image of the target is not generated, there are also no privacy concerns. Detection is real-time and entirely computer-based, which means there is no need for human operators to alert security. This eliminates the safety concerns of a would-be operator, reduces the expense of a human operator, and enables overall accuracy of 93%.

The technology is designed to identify if someone is carrying a gun, knife, suicide vest, etc., by analyzing metal content and relating it to a database of known weapon signatures. Patriot One believes the widespread use of this detection technology could act as an effective deterrent, thereby diminishing the epidemic phenomena of active shooters across the nation and around the world.

The company is guided by a team of experts in the areas of high-frequency electromagnetics, counter-terrorism, conflict resolution, government/corporate interface, sensor development, proactive security and business development. Senior Management has partnered with, among other affiliates, Ridge Global, which was founded by recently appointed advisory board member Tom Ridge, the first head of the Department of Homeland Security, first U.S. Secretary of Homeland Security, and 43rd governor of Pennsylvania.

Along with its partners, Patriot One is addressing global concerns of active shooting events and other violent terrorist attacks. The key is to short-circuit the event through effective prevention technologies and security protocols. Disclaimer

Patriot One Technologies, Inc. Company Blog

Patriot One Technologies, Inc. News:

Patriot One Completes FCC and IC Submission in Preparation for PATSCAN CMR Commercialization

NetworkNewsWire Releases Exclusive Audio Interview with Patriot One Technologies, Inc. (PTOTF)

Patriot One Initiates Pacific Rim Sales with Aotea Security of New Zealand

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

StockMarketWatch
(APVO) +58.65%

2.

MarketBeat
(SDRL) +48.07%

3.

QualityStocks
(BKIT) +36.00%

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















 

The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251